Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells $563,400.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $56.34, for a total transaction of $563,400.00. Following the completion of the transaction, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at $38,127,756.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Helen Torley also recently made the following trade(s):

• On Tuesday, September 10th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $59.09, for a total value of $590,900.00.
• On Thursday, September 12th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $59.20, for a total value of $592,000.00.

Halozyme Therapeutics Trading Up 0.0 %

NASDAQ HALO opened at $56.97 on Friday. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The company has a market capitalization of $7.25 billion, a price-to-earnings ratio of 23.54, a PEG ratio of 0.56 and a beta of 1.28. The stock’s 50-day simple moving average is $58.67 and its two-hundred day simple moving average is $49.68. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The firm’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.68 EPS. Research analysts forecast that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. TD Cowen boosted their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. The Goldman Sachs Group boosted their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday, June 7th. HC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, September 13th. Finally, Morgan Stanley upped their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of HALO. Rise Advisors LLC bought a new position in Halozyme Therapeutics during the 1st quarter worth approximately $25,000. Whittier Trust Co. purchased a new stake in shares of Halozyme Therapeutics during the first quarter valued at approximately $27,000. GAMMA Investing LLC grew its holdings in shares of Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares during the last quarter. International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at $33,000. Finally, Skandinaviska Enskilda Banken AB publ bought a new position in shares of Halozyme Therapeutics during the second quarter valued at about $49,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.